# OnCo record nct05933265 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05933265/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05933265", "NCT05933265" ;
  schema:name "Study of LP-184 in Patients With Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05933265/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05933265> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-06-09" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/lp-184/> ;
  onco:companies <https://onco.cc/companies/lantern-pharma/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05933265-invest-new-drugs-2026/> .